Advertisement

Recent advances in cutaneous lymphomas

      Summary

      Cutaneous lymphomas are a heterogeneous group of extranodal lymphomas that are characterized by an initial accumulation of mononuclear, mostly lymphocytic cells in the skin. Recent discoveries of changes in molecular biology and immunology of these tumors have paved the way to a better understanding of the processes that govern lymphomagenesis in the skin and more importantly, they have contributed to the development of the new WHO-EORTC classification system. Only now has the field of cutaneous lymphomas gained a novel, long-awaited basis that may act as a new starting point in the collection of clinical as well molecular and immunological data on comparative basis. This review will try to highlight the newest findings in the pathogenesis of primary cutaneous T- and B-cell lymphomas, hematodermic neoplasm and HTLV-1 positive disorders as well as their translation into efficient therapeutic strategies.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Dermatological Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Vogelstein B.K.K.
        The multistep nature of cancer.
        Trends Genet. 1993; 9: 138-141
        • Qin J.-Z.N.F.
        • Häffner A.
        • Dummer R.
        • Burg G.
        • Döbbeling U.
        Cutaneous T cell lymphoma cells contain constitutive NFkB complexes.
        J Invest Derm. 1997; 1997: 575
        • Qin J.-Z.K.J.
        • Zhang C.-L.
        • Dummer R.
        • Burg G.
        • Döbbeling U.
        Constitutive and IL-7 and IL-15 stimulated DNA-binding of STAT and novel factors in cutaneous T cell lymphoma (CTCL) cells.
        J Invest Derm. 2001; 117: 583-589
        • Qin J.-Z.Z.C.-L.
        • Kamarashev J.
        • Dummer R.
        • Burg G.
        • Döbbeling U.
        IL-7 and IL-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T cell lymphoma (CTCL) cells.
        Blood. 2001; 98: 2778-2783
        • Qin J.-Z.D.R.
        • Burg G.
        • Döbbeling U.
        Constitutive and IL-7/Il-15 stimulated DNA-binding of Myc, Jun, and novel Myc-like proteins in cutaneous T cell Lymphoma cells.
        Blood. 1999; 93: 260-267
        • Saharinen P.E.N.
        • Sarvas K.
        • Parker P.
        • Alitalo K.
        • Silvennoinen O.
        The Bmx tyrosine kinase induces activation of the STAT signaling pathway, which is specifically inhibited by protein kinase Cdelta.
        Blood. 1997; 90: 4341-4353
        • Döbbeling U.D.R.
        • Laine E.
        • Potoczna N.
        • Qin J.-Z.
        • Burg G.
        IL-15 is an autocrine/paracrine viability factor for cutaneous T cell lymphoma cells.
        Blood. 1998; 92: 252-258
        • Campbell G.S.Y.C.
        • Jove R.
        • Carter-Su C.
        Constitutive activation of JAK1 in Src-transformed cells.
        J Biol Chem. 1997; 272: 2591-2594
        • Li G.C.L.
        • Wolfe J.T.
        • Rook A.H.
        • Felix A.C.
        • Lessin S.R.
        • Salhany K.E.
        Overexpression of p53 protein in cutaneous T cell lymphoma: relationship to large cell transformation and disease progression.
        J Invest Dermatol. 1998; 110: 767-770
        • Karenko L.H.S.
        • Paivinen S.
        • Karhu R.
        • Syrja S.
        • Kahkonen M.
        • Nedoszytko B.
        • et al.
        Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue.
        Cancer Res. 2005; 65: 8101-8110
        • Burg G.
        • Kempf W.
        • Cozzio A.
        • Feit J.
        • Willemze R.
        • SJ E.
        • et al.
        WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects.
        J Cutan Pathol. 2005; 32: 647-674
        • Willemze R.
        • Jaffe E.S.
        • Burg G.
        • Cerroni L.
        • Berti E.
        • Swerdlow S.H.
        • et al.
        WHO-EORTC classification for cutaneous lymphomas.
        Blood. 2005; 105: 3768-3785
        • Cerroni L.
        • Gatter K.
        • Kerl H.
        An illustrated guide to skin lymphoma.
        Blackwell, Oxford2004
        • Goerdt S.
        • Spieker T.
        • Wolffer L.U.
        Multiple cutaneous B-cell pseudolymphomas after allergen injections.
        J Am Acad Dermatol. 1996; 34: 1072-1074
        • Crowson A.N.
        • Magro C.M.
        Antidepressant therapy. A possible cause of atypical cutaneous lymphoid hyperplasia.
        Arch Dermatol. 1995; 131: 925-929
        • Peretz E.
        • Grunwald M.H.
        • Cagnano E.
        • Halevy S.
        Follicular B-cell pseudolymphoma.
        Australas J Dermatol. 2000; 41: 48-49
        • Landa N.G.
        • Zelickson B.D.
        • Peters M.S.
        • Muller S.A.
        • Pittelkow M.R.
        Lymphoma versus pseudolymphoma of the skin: gene rearrangement study of 21 cases with clinicopathologic correlation.
        J Am Acad Dermatol. 1993; 29: 945-953
        • Bouloc A.
        • Delfau-Larue M.H.
        • Lenormand B.
        • Meunier F.
        • Wechsler J.
        • Thomine E.
        • et al.
        Polymerase chain reaction analysis of immunoglobulin gene rearrangement in cutaneous lymphoid hyperplasias. French Study Group for cutaneous lymphomas.
        Arch Dermatol. 1999; 135: 168-172
        • Sangueza O.P.
        • Yadav S.
        • White Jr., C.R.
        • Braziel R.M.
        Evolution of B-cell lymphoma from pseudolymphoma. A multidisciplinary approach using histology, immunohistochemistry, and Southern blot analysis.
        Am J Dermatopathol. 1992; 14: 408-413
        • Hammer E.
        • Sangueza O.
        • Suwanjindar P.
        • White Jr., C.R.
        • Braziel R.M.
        Immunophenotypic and genotypic analysis in cutaneous lymphoid hyperplasias.
        J Am Acad Dermatol. 1993; 28: 426-433
        • Cerroni L.
        • Zochling N.
        • Putz B.
        • Kerl H.
        Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma.
        J Cutan Pathol. 1997; 24: 457-461
        • Goodlad J.R.
        • Davidson M.M.
        • Hollowood K.
        • Batstone P.
        • Ho-Yen D.O.
        Borrelia burgdorferi-associated cutaneous marginal zone lymphoma: a clinicopathological study of two cases illustrating the temporal progression of B. burgdorferi-associated B-cell proliferation in the skin.
        Histopathology. 2000; 37: 501-508
        • Streubel B.
        • Lamprecht A.
        • Dierlamm J.
        • Cerroni L.
        • Stolte M.
        • Ott G.
        • et al.
        T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma.
        Blood. 2003; 101: 2335-2339
        • Streubel B.
        • Simonitsch-Klupp I.
        • Mullauer L.
        • Lamprecht A.
        • Huber D.
        • Siebert R.
        • et al.
        Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites.
        Leukemia. 2004; 18: 1722-1726
        • Streubel B.
        • Vinatzer U.
        • Lamprecht A.
        • Raderer M.
        • Chott A.
        T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma.
        Leukemia. 2005; 19: 652-658
        • Schreuder M.I.
        • Hoefnagel J.J.
        • Jansen P.M.
        • van Krieken J.H.
        • Willemze R.
        • Hebeda K.M.
        FISH analysis of MALT lymphoma-specific translocations and aneuploidy in primary cutaneous marginal zone lymphoma.
        J Pathol. 2005; 205: 302-310
        • Grange F.
        • Petrella T.
        • Beylot-Barry M.
        • Joly P.
        • D’Incan M.
        • Delaunay M.
        • et al.
        Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas.
        Blood. 2004; 103: 3662-3668
        • Hoefnagel J.J.
        • Dijkman R.
        • Basso K.
        • Jansen P.M.
        • Hallermann C.
        • Willemze R.
        • et al.
        Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling.
        Blood. 2005; 105: 3671-3678
        • Wright G.
        • Tan B.
        • Rosenwald A.
        • Hurt E.H.
        • Wiestner A.
        • Staudt L.M.
        A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.
        Proc Natl Acad Sci USA. 2003; 100: 9991-9996
        • Dijkman R.
        • Tensen C.P.
        • Buettner M.
        • Niedobitek G.
        • Willemze R.
        • Vermeer M.H.
        Primary cutaneous follicle center lymphoma and primary cutaneous large B-cell lymphoma, leg type are both targeted by aberrant somatic hypermutation but demonstrate differential expression of AID.
        Blood. 2006; 107: 4926-4929
        • Petrella T.
        • Bagot M.
        • Willemze R.
        • Beylot-Barry M.
        • Vergier B.
        • Delaunay M.
        • et al.
        Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review.
        Am J Clin Pathol. 2005; 123: 662-675
        • Jacob M.C.
        • Chaperot L.
        • Mossuz P.
        • Feuillard J.
        • Valensi F.
        • Leroux D.
        • et al.
        CD4+CD56+ lineage negative malignancies: a new entity developed from malignant early plasmacytoid dendritic cells.
        Haematologica. 2003; 88: 941-955
        • Chan J.K.C.
        • Jaffe E.S.
        • Ralfkiaer E.
        Blastic NK-cell lymphoma.
        Pathology and genetics of tumours of haematopoietic and lymphoid tissues (World Health Organization classification of tumours). IARC Press, Lyon, France2001 (p. 214–215)
        • Spits H.
        • Lanier L.L.
        • Phillips J.H.
        Development of human T and natural killer cells.
        Blood. 1995; 85: 2654-2670
        • Chaperot L.
        • Bendriss N.
        • Manches O.
        • Gressin R.
        • Maynadie M.
        • Trimoreau F.
        • et al.
        Identification of a leukemic counterpart of the plasmacytoid dendritic cells.
        Blood. 2001; 97: 3210-3217
        • Herling M.
        • Teitell M.A.
        • Shen R.R.
        • Medeiros L.J.
        • Jones D.
        TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+CD56+ blastic tumors of skin.
        Blood. 2003; 101: 5007-5009
        • Petrella T.
        • Meijer C.J.
        • Dalac S.
        • Willemze R.
        • Maynadie M.
        • Machet L.
        • et al.
        TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NK-cell lymphomas) and leukemia cutis.
        Am J Clin Pathol. 2004; 122: 307-313
        • Feuillard J.
        • Jacob M.C.
        • Valensi F.
        • Maynadie M.
        • Gressin R.
        • Chaperot L.
        • et al.
        Clinical and biologic features of CD4(+)CD56(+) malignancies.
        Blood. 2002; 99: 1556-1563
        • Garnache-Ottou F.
        • Chaperot L.
        • Biichle S.
        • Ferrand C.
        • Remy-Martin J.P.
        • Deconinck E.
        • et al.
        Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells.
        Blood. 2005; 105: 1256-1264
        • Urosevic M.
        • Conrad C.
        • Kamarashev J.
        • Asagoe K.
        • Cozzio A.
        • Burg G.
        • et al.
        CD4+CD56+ hematodermic neoplasms bear a plasmacytoid dendritic cell phenotype.
        Hum Pathol. 2005; 36: 1020-1024
        • Dzionek A.
        • Sohma Y.
        • Nagafune J.
        • Cella M.
        • Colonna M.
        • Facchetti F.
        • et al.
        BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction.
        J Exp Med. 2001; 194: 1823-1834
        • MacDonald K.P.
        • Munster D.J.
        • Clark G.J.
        • Dzionek A.
        • Schmitz J.
        • Hart D.N.
        Characterization of human blood dendritic cell subsets.
        Blood. 2002; 100: 4512-4520
        • Petrella T.
        • Comeau M.R.
        • Maynadie M.
        • Couillault G.
        • De Muret A.
        • Maliszewski C.R.
        • et al.
        ‘Agranular CD4+ CD56+ hematodermic neoplasm’ (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes.
        Am J Surg Pathol. 2002; 26: 852-862
        • Chaperot L.
        • Perrot I.
        • Jacob M.C.
        • Blanchard D.
        • Salaun V.
        • Deneys V.
        • et al.
        Leukemic plasmacytoid dendritic cells share phenotypic and functional features with their normal counterparts.
        Eur J Immunol. 2004; 34: 418-426
        • Poiesz B.J.
        • Ruscetti F.W.
        • Gazdar A.F.
        • Bunn P.A.
        • Minna J.D.
        • Gallo R.C.
        Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.
        Proc Natl Acad Sci USA. 1980; 77: 7415-7419
        • Yoshida M.
        • Miyoshi I.
        • Hinuma Y.
        Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease.
        Proc Natl Acad Sci USA. 1982; 79: 2031-2035
        • Manel N.
        • Kim F.J.
        • Kinet S.
        • Taylor N.
        • Sitbon M.
        • Battini J.L.
        The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV.
        Cell. 2003; 115: 449-459
        • Blattner W.A.
        Human retroviruses: their role in cancer.
        Proc Assoc Am Physic. 1999; 111: 563-572
        • Edlich R.F.
        • Arnette J.A.
        • Williams F.M.
        Global epidemic of human T-cell lymphotropic virus type-I (HTLV-I).
        J Emerg Med. 2000; 18: 109-119
        • Proietti F.A.
        • Carneiro-Proietti A.B.
        • Catalan-Soares B.C.
        • Murphy E.L.
        Global epidemiology of HTLV-I infection and associated diseases.
        Oncogene. 2005; 24: 6058-6068
        • Fujiyoshi T.
        • Yashiki S.
        • Fujiyama C.
        • Kuwayama M.
        • Miyashita H.
        • Ohnishi H.
        • et al.
        Ethnic segregation of HTLV-I and HTLV-II carriers among South American native Indians.
        Int J Cancer. 1995; 63: 510-515
        • Parker C.E.
        • Daenke S.
        • Nightingale S.
        • Bangham C.R.
        Activated, HTLV-1-specific cytotoxic T-lymphocytes are found in healthy seropositives as well as in patients with tropical spastic paraparesis.
        Virology. 1992; 188: 628-636
        • Arnulf B.
        • Thorel M.
        • Poirot Y.
        • Tamouza R.
        • Boulanger E.
        • Jaccard A.
        • et al.
        Loss of the ex vivo but not the reinducible CD8+ T-cell response to Tax in human T-cell leukemia virus type 1-infected patients with adult T-cell leukemia/lymphoma.
        Leukemia. 2004; 18: 126-132
        • Grassmann R.
        • Aboud M.
        • Jeang K.T.
        Molecular mechanisms of cellular transformation by HTLV-1 Tax.
        Oncogene. 2005; 24: 5976-5985
        • Yoshida M.
        Multiple viral strategies of HTLV-1 for dysregulation of cell growth control.
        Annu Rev Immunol. 2001; 19: 475-496
        • Karube K.
        • Ohshima K.
        • Tsuchiya T.
        • Yamaguchi T.
        • Kawano R.
        • Suzumiya J.
        • et al.
        Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/lymphoma cells.
        Br J Haematol. 2004; 126: 81-84
        • Roncador G.
        • Garcia J.F.
        • Garcia J.F.
        • Maestre L.
        • Lucas E.
        • Menarguez J.
        • et al.
        FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma.
        Leukemia. 2005; 19: 2247-2253
        • Kohno T.
        • Yamada Y.
        • Akamatsu N.
        • Kamihira S.
        • Imaizumi Y.
        • Tomonaga M.
        • et al.
        Possible origin of adult T-cell leukemia/lymphoma cells from human T lymphotropic virus type-1-infected regulatory T cells.
        Cancer Sci. 2005; 96: 527-533
        • Matsubara Y.
        • Hori T.
        • Morita R.
        • Sakaguchi S.
        • Uchiyama T.
        Phenotypic and functional relationship between adult T-cell leukemia cells and regulatory T cells.
        Leukemia. 2005; 19: 482-483
        • Dosaka N.
        • Tanaka T.
        • Miyachi Y.
        • Imamura S.
        • Kakizuka A.
        Examination of HTLV-I integration in the skin lesions of various types of adult T-cell leukemia (ATL): independence of cutaneous-type ATL confirmed by Southern blot analysis.
        J Invest Dermatol. 1991; 96: 196-200
        • Takahashi K.
        • Tanaka T.
        • Fujita M.
        • Horiguchi Y.
        • Miyachi Y.
        • Imamura S.
        Cutaneous-type adult T-cell leukemia/lymphoma. A unique clinical feature with monoclonal T-cell proliferation detected by Southern blot analysis.
        Arch Dermatol. 1988; 124: 399-404
        • Yoshie O.
        • Fujisawa R.
        • Nakayama T.
        • Harasawa H.
        • Tago H.
        • Izawa D.
        • et al.
        Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells.
        Blood. 2002; 99: 1505-1511
        • Hasegawa H.
        • Nomura T.
        • Kohno M.
        • Tateishi N.
        • Suzuki Y.
        • Maeda N.
        • et al.
        Increased chemokine receptor CCR7/EBI1 expression enhances the infiltration of lymphoid organs by adult T-cell leukemia cells.
        Blood. 2000; 95: 30-38
        • Harashima N.
        • Kurihara K.
        • Utsunomiya A.
        • Tanosaki R.
        • Hanabuchi S.
        • Masuda M.
        • et al.
        Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation.
        Cancer Res. 2004; 64: 391-399
        • Mori N.
        • Yamada Y.
        • Ikeda S.
        • Yamasaki Y.
        • Tsukasaki K.
        • Tanaka Y.
        • et al.
        Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells.
        Blood. 2002; 100: 1828-1834
        • Zhang Z.
        • Zhang M.
        • Goldman C.K.
        • Ravetch J.V.
        • Waldmann T.A.
        Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
        Cancer Res. 2003; 63: 6453-6457
        • Willemze R.
        • Kerl H.
        • Sterry W.
        • Berti E.
        • Cerroni L.
        • Chimenti S.
        • et al.
        EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer.
        Blood. 1997; 90: 354-371
        • Jaffe E.S.
        • Harris N.L.
        • Stein H.
        • Vardiman J.W.
        Tumours of hematopoietic and lymphoid tissues.
        World Health Organization classification of tumours. IARC Press, Lyon, France2001
        • Marks P.A.
        • Richon V.M.
        • Miller T.
        • Kelly W.K.
        Histone deacetylase inhibitors.
        Adv Cancer Res. 2004; 91: 137-168
        • Bayes M.
        • Rabasseda X.
        • Prous J.R.
        Gateways to clinical trials.
        Meth. Find Exp Clin Pharmacol. 2004; 26: 357-391
        • Foss F.M.
        Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma.
        Ann N Y Acad Sci. 2001; 941: 166-176
        • Olsen E.
        • Duvic M.
        • Frankel A.
        • Kim Y.
        • Martin A.
        • Vonderheid E.
        • et al.
        Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.
        J Clin Oncol. 2001; 19: 376-388
        • Gorgun G.
        • Foss F.
        Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox.
        Blood. 2002; 100: 1399-1403
        • Foss F.
        • Demierre M.F.
        • Divenuti G.
        A Phase I trial of Bexarotene and Denileukin Diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma.
        Blood. 2005; 107: 4926-4929
        • Flynn J.M.
        • Byrd J.C.
        Campath-1H monoclonal antibody therapy.
        Curr Opin Oncol. 2000; 12: 574-581
        • Lundin J.
        • Hagberg H.
        • Repp R.
        • Cavallin Stahl E.
        • Freden S.
        • Juliusson G.
        • et al.
        Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome.
        Blood. 2003; 101: 4267-4272
        • Lundin J.
        • Kennedy B.
        • Dearden C.
        • Dyer M.J.
        • Osterborg A.
        No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sezary syndrome.
        Blood. 2005; 105: 4148-4149
        • Lenihan D.J.
        • Alencar A.J.
        • Yang D.
        • Kurzrock R.
        • Keating M.J.
        • Duvic M.
        Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome.
        Blood. 2004; 104: 655-658
        • Hagberg H.
        • Pettersson M.
        • Bjerner T.
        • Enblad G.
        Treatment of a patient with a nodal peripheral T-cell lymphoma (angioimmunoblastic T-cell lymphoma) with a human monoclonal antibody against the CD4 antigen (HuMax-CD4).
        Med Oncol. 2005; 22: 191-194
        • Engert A.
        • Burrows F.
        • Jung W.
        • Tazzari P.L.
        • Stein H.
        • Pfreundschuh M.
        • et al.
        Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.
        Cancer Res. 1990; 50: 84-88
        • Klimka A.
        • Barth S.
        • Matthey B.
        • Roovers R.C.
        • Lemke H.
        • Hansen H.
        • et al.
        An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA’) is a potent immunotoxin against a Hodgkin-derived cell line.
        Br J Cancer. 1999; 80: 1214-1222
        • Matthey B.
        • Borchmann P.
        • Schnell R.
        • Tawadros S.
        • Lange H.
        • Huhn M.
        • et al.
        Metalloproteinase inhibition augments antitumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA’ against human lymphomas in vivo.
        Int J Cancer. 2004; 111: 568-574
        • Schnell R.
        • Linnartz C.
        • Katouzi A.A.
        • Schon G.
        • Bohlen H.
        • Horn-Lohrens O.
        • et al.
        Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen.
        Int J Cancer. 1995; 63: 238-244
        • Zhang C.
        • Richon V.
        • Ni X.
        • Talpur R.
        Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
        J Invest Dermatol. 2005; 125: 1045-1052

      Biography

      Reinhard Dummer is the Head of the Skin Cancer Unit, Department of Dermatology, University Hospital, Zurich. He has worked for more than a decade on cutaneous malignancies including non-melanoma skin cancers, melanoma and cutaneous T-cell lymphomas reflected by more than 150 original articles.
      He is a board member of the European Society for Dermatological Research, the European Association for dermatological oncology (EADO) and the International Society for Cutaneous Lymphomas (ISCL). In 2003, he was honoured with the German Cancer Award for translational research by the German Cancer Society.